NEW: Updated NCCN MM Guidelines Strengthen Recommendation for Baseline Clonotype ID at Diagnosis.
Covered by Medicare and FDA-cleared, clonoSEQ supports baseline ID assessment to enable subsequent next generation sequencing (NGS)-based MRD tracking. For more info about incorporating clonoSEQ into your clinical practice for MM patients, click here.
Resources
Materials for you and your practice
Download helpful materials to keep information nearby about the basics of clonoSEQ, specimen requirements, and more.
clonoSEQ HCP Brochure
Everything you need to know about clonoSEQ, including how it benefits patients, in one resource.
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.